The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ovcharov P.S.

Nasonova Research Institute of Rheumatology, Moscow, Russia

Lisitsyna T.A.

Nauchno-issledovatel'skiĭ institut revmatologii RAMN

Vel'tishchev D.Iu.

Moskovskiĭ NII psikhiatrii

Tardov M.V.

GBUZ "Moskovskiĭ nauchno-prakticheskiĭ tsentr otorinolaringologii im. L.I. Sverzhevskogo" Departamenta zdravookhraneniia Moskvy

Burenchev D.V.

Gorodskaia klinicheskaia bol'nitsa #20, Moskva

Alekberova Z.S.

Nauchno-issledovatel'skiĭ institut revmatologii im. V.A. Nasonovoĭ RAN, Moskva

Nasonov E.L.

"Research Institute of rheumatology n. a. V. A. Nasonova"

Neurological and psychiatric disorders in Behҫet’s disease

Authors:

Ovcharov P.S., Lisitsyna T.A., Vel'tishchev D.Iu., Tardov M.V., Burenchev D.V., Alekberova Z.S., Nasonov E.L.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(6): 76‑86

DOI: 10.17116/jnevro20161166176-86

Views: 5907

Downloaded: 96

Download PDF (RU)
Contact the author
Table of contents

NEUROLOGICAL AND PSYCHIATRIC DISORDERS IN BEHҪET’S DISEASE
NEUROLOGICAL AND PSYCHIATRIC DISORDERS IN BEHҪET’S DISEASE

To cite this article:

Ovcharov PS, Lisitsyna TA, Vel'tishchev DIu, Tardov MV, Burenchev DV, Alekberova ZS, Nasonov EL. Neurological and psychiatric disorders in Behҫet’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(6):76‑86. (In Russ.)
https://doi.org/10.17116/jnevro20161166176-86

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata

The data of the literature on epidemiology, clinical manifestations, diagnosis and treatment of Behcet’s disease are presented. Particular attention is paid to international recommendations (2014) on the classification, diagnostic criteria and treatment of neurological symptoms of Behҫet disease.

Keywords:

psychiatric disorders
neurological disorders
depression
neurological Behçet disease
diagnosis
therapy

Authors:

Ovcharov P.S.

Nasonova Research Institute of Rheumatology, Moscow, Russia

Lisitsyna T.A.

Nauchno-issledovatel'skiĭ institut revmatologii RAMN

Vel'tishchev D.Iu.

Moskovskiĭ NII psikhiatrii

Tardov M.V.

GBUZ "Moskovskiĭ nauchno-prakticheskiĭ tsentr otorinolaringologii im. L.I. Sverzhevskogo" Departamenta zdravookhraneniia Moskvy

Burenchev D.V.

Gorodskaia klinicheskaia bol'nitsa #20, Moskva

Alekberova Z.S.

Nauchno-issledovatel'skiĭ institut revmatologii im. V.A. Nasonovoĭ RAN, Moskva

Nasonov E.L.

"Research Institute of rheumatology n. a. V. A. Nasonova"

List of references:

  1. Alekberova ZS. Bolezn' Behcheta. Monografija. M. 2007. (In Russ.).
  2. International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078-1080. doi: 10.1016/0140-736(90)92643-V.
  3. Saadoun D, Wechsler B, Desseaux K, Le Thi Huong D, Amoura Z, Resche-Rigon M, Cacoub P. Mortality in Behçet’s Disease. Arthritis & Rheumatism. 2010;62(9):2806-2812. doi: 10.1002/art.27568.
  4. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients-The Neuro-Behcet Study Group. Brain. 1999;122:2171-2182. doi: 10.1093/brain/122.11.2171.
  5. Byung-Sik Cho, Hyun-Sook Kim, Su-Jin Oh, Hyeok-Jae Koh, Chong-Hyun Yoon, So-Lyung Jung, Do-June Min, Wan-Uk Kim. Comparison of the сlinical manifestations, brain MRI and prognosis between Neuro-Behçet's Disease and Neuropsychiatric Lupus. The Korean Journal of Internal Medicine. 2007;22:77-86.  doi: 10.3904/kjim.2007.22.2.77.
  6. Haddou Ait Ben E, Benomar A, Regragui W, Yahyaoui M. Neurological manifestations in Behçet Disease. Rev Neurol (Paris). 2012;168(4):344-349.  doi: 10.1016/j.neurol.2011.09.006.
  7. Sang-Kook Lee, Sung-Jae Choi, Sang-Dae Kim, Dong-Jun Lim. Rapid atypical progression of neuro-Behçet’s Disease involving whole brainstem and bilateral thalami. J Korean Neurosurg Soc. 2011;50:68-71.  doi: 10.3340/jkns.2011.50.1.68.
  8. Cardoso A, Rocha-Filho P, Melo Correa-Lima A. Neuro-Behçet: differential diagnosis of recurrent meningitis. Rev Med Chile. 2013;141:114-118.  doi: 10.4067/S0034-98872013000100016.
  9. Kikuchi T, Yokoe I, Masuyama A, Maniwa K, Tsuruta Sh, Hatanaka Y, Haraoka H. Behçet’s Disease initially presenting with meningitis and sudden hearing loss. Inter Med. 2010;49:483-486.  doi: 10.4067/S0034-98872013000100016.
  10. Dolan R, Watson S, Bathgate D. Behçet’s disease presenting as new onset of confusion in a male patient of North African origin in the UK. BMJ Case Reports. 2010. doi: 10.1136/bcr.05.2010.2982.
  11. Zayed H, Effat D, Nawito Z, Abdou AA, El Din MN, El-Refaei S, Amin M, Mohamed Y, Amin A, Wafie A, Abu El-Einin K. Silent central nervous system involvement in Egyptian Behçet's disease patients: clinical, psychiatric, and neuroimaging evaluation. Clin Rheumatol. 2011;30(9):1173-1180. doi: 10.1007/s10067-011-1725-2.
  12. Cavaco S, da Silva AM, Pinto P, Coutinho E, Santos E, Bettencourt A, Pinto C, Gonçalves A, Silva S, Gomes F, Carvalho L, Pereira C, Martins B, Correia J, Vasconcelos C. Cognitive functioning in Behcet’s Disease. Ann N Y Acad Sci. 2009;1173:217-226.  doi: 10.1111/j.1749-6632.2009.04670.x.
  13. Yesilot N, Shehu M, Oktem-Tanor O, Serdaroglu P, Akman-Demir G. Silent neurological involvement in Behcet’s disease. Clin Exp Rheumatol. 2006;24(5 suppl 42):65-70.
  14. Kalashnikova LA, Alekberova ZS, Reshetnjak TM i dr. Nevrologicheskie projavlenija bolezni Behcheta: obzor literatury i opisanie sobstvennogo nabljudenija. Nevrologicheskij zhurnal. 2001;6:8-13. (In Russ.).
  15. Alekberova ZS, Kalashnikova LA, Goloeva RG, Elonakov AV. Nevrologicheskie projavlenija bolezni Behcheta. Nauchno-prakticheskaja revmatologija. 2007;3:109-113. (In Russ.). doi: 10.14412/1995-4484-2007-697.
  16. Hirohata Sh, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, Ishigatsubo Y. Clinical characteristics of neuro-Behçet’s disease in Japan: a multicenter retrospective analysis. Mod Rheumatol. 2012;22:405-413.  doi: 10.1007/s10165-011-0533-5.
  17. Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, Houman H, Mahr A, Salvarani C, Sfikakis PP, Siva A, Al-Araji A. Diagnosis and management of Neuro-Behçet's disease: internationalconsensus recommendations. J Neurol. 2014;261(9):1662-1676. doi: 10.1007/s00415-013-7209-3.
  18. Hatemi G, Silman A, Bang D et al. Management of Behçet’s disease: a systematic literature review for the EULAR evidence based recommendations for the management of Behcet’s disease. Ann Rheum Dis. 2008;67:1656-1662. doi: 10.1136/ard.2008.087957.
  19. Garcia-Burillo A, Castell J, Fraile M, Jacas C, Vilardell M, Ortega D, Bosch J-A. Technetium-99m-HMPAO Brain SPECT in Behçet's Disease. J Nuc I Med. 1998;39:950-954.
  20. Abdelraheem T, Habib HM, Eissa AA, Radwan NM. Psychiatric disorders andMRI brain findings in patients withsystemic lupus erythematosus andBehcet's disease: a cross sectional study. Acta Reumatol Port. 2013;38(4):252-260.
  21. Ishhenko DA, Vel'tishhev DJu, Alekberova ZS, Lisicyna TA, Kovalevskaja OB, Seravina OF, Krasnov VN, Nasonov EL. Psihotravmirujushhie faktory i rasstrojstva trevozhno-depressivnogo spektra pri bolezni Behcheta. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2014;114:11:14-19. (In Russ.).
  22. Uğuz F, Dursun R, Kaya N et al. Quality of life in patients with Behçet's disease: the impact of major depression. Gen Hosp Psychiatry. 2007;29(1):21-24.  doi: 10.1016/j.genhosppsych.2006.10.001.
  23. Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1013-1019.
  24. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101-2107. doi: 10.1001/archinte.160.14.2101.
  25. Rathbun AM, Reed GW, Harrold LR. The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review. Rheumatology. 2013;52(10):1785-1794. doi: 10.1093/rheumatology/kes356.
  26. Gür A, Sarac AJ, Burkan YK, Nas K, Cevik R. Arthropathy, quality of life, depression, and anxiety in Behçet's disease: relationship between arthritis and these factors. Clin Rheumatol. 2006;25(4):524-531.  doi: 10.1007/s10067-005-0100-6.
  27. Hoeven J, Duyx J, Langen JJ et al. Probable psychiatric side effects of azathioprine. Psychosomatic Medicine. 2005;67:508.  doi: 10.1097/01.psy.0000160473.31162.4d.
  28. Nkam I, Cottereau MJ. Acute psychosis and Behçet's disease: a case report. Encephale. 2006;32(3 Pt 1):385-388.  doi: 10.1016/S0013-7006(06)77335-3.
  29. Nakano Y, Hatanaka Y, Ikebuchi E, Shimizu T, Nanko S, Utsumii T. A case of Neuro-Behçet's disease with early onset of bipolar mood disorder. Seishin Shinkeigaku Zasshi. 2004;106(5):564-573.
  30. Talarico R, d'Ascanio A, Figus M, Stagnaro C, Ferrari C, Elefante E, Baldini C, Tani C, Mosca M, Bombardieri S. Behçet's disease: features of neurological involvement in a dedicated centre in Italy. Clin Exp Rheumatol. 2012;30(3 suppl 72):69-72.
  31. Dutra LA, de Souza AW, Alessi H et al. Cognitive impairment in Brazilian patients with Behçet's disease occurs independently of neurologic manifestation. J Neurol Sci. 2013;327(1-2):1-5.  doi: 10.1016/j.jns.2013.01.024.
  32. Erberk-Ozen N, Birol A, Boratav C, Kocak M. Executive dysfunctions and depression in Behçet's disease without explicit neurological involvement. Psychiatry Clin Neurosci. 2006;60(4):465-72.  doi: 10.1111/j.1440-1819.2006.01533.x.
  33. Calikoglu E, Onder M, Cosar B, Candansayar S. Depression, anxiety levels and general psychological profile in Behçet's disease. Dermatology. 2001;203(3):238-240.  doi: 10.1159/000051756.
  34. Tascilar NF, Tekin NS, Ankarali H, Sezer T, Atik L, Emre U, Duysak S, Cinar F. Sleep disorders in Behçet's disease, and their relationship with fatigue and quality of life. J Sleep Res. 2012;21(3):281-288.  doi: 10.1111/j.1365-2869.2011.00976.x.
  35. Ediz L, Hiz O, Toprak M, Ceylan MF, Yazmalar L, Gulcu E. Restless legs syndrome in Behçet's disease. J Int Med Res. 2011;39(3):759-765.  doi: 10.1177/147323001103900307.
  36. Koçak M, Başar MM, Vahapoğlu G. The effect of Behçet's disease on sexual function and psychiatric status of premenopausal women. J Sex Med. 2009;6(5):1341-1348. doi: 10.1111/j.1743-6109.2008.01078.x.
  37. Hiz O, Ediz L, Gülcü E. Effects of Behçet's disease on sexual function and psychological status of male patients. J Sex Med. 2011;8(5):1426-1433. doi: 10.1111/j.1743-6109.2010.02040.x.
  38. Koçer A, Koçer E, Canan F, Çağrıcı S. Memantin responsive Behcet’s disease with initial onset severe cognitive decline. Eur J Gen Med. 2007;4(3):138-140.
  39. International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD), Davatchi F, Assaad-Khalil S. et al. The international criteria for Behçet’s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2013. doi: 10.1111/jdv.12107.
  40. Akman-Demir G, Erdem Tuzun, Sema Icoz et al. Interleukin-6 in neuro-Behçet’s disease: association with disease subsets and long-term outcome. Cytokine. 2008;44:373-376.  doi: 10.1016/j.cyto.2008.10.007.
  41. Saruhan-Direskeneli G, Yentur SP, Akman-Demir G, Isik N, Serdaroglu P. Cytokines and chemokines in neuro-Behcet’s disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol. 2003;145:127-134. doi: http://dx.doi.org/10.1016/j.jneuroim.2003.08.040.
  42. Budak-Alpdogan T, Demirçay, Alpdogan O et al. Skin hyperreactivity of Behçet’s patients (pathergy reaction) is also positive in interferon alpha-treated chronic myeloid leukaemia patients, indicating similarly altered neutrophil functions in both disorders. Br J Rheumatol. 1998;37:1148-1151. doi: 10.1093/rheumatology/37.11.1148.
  43. Hatemi I, Hatemi G, Celik AF et al. Frequency of pathergy phenomenon and other features of Behçet’s syndrome among patients with inflammatory bowel disease. Clin Exp Rheumatol. 2008;26(4 suppl 50):91-95.
  44. Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatol (Oxford). 2012;51:887-900.  doi: 10.1093/rheumatology/ker428.
  45. Al-Araji A, Kidd DP. Neuro-Behcet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8:192-204.  doi: 10.1016/S1474-4422(09)70015-8.
  46. Turker H, Terzi M, Bayrak O, Cengiz N, Onar M, Us O. Visual evoked potentials in differential diagnosis of multiple sclerosis and neurobehcet’s disease. Tohoku J Exp Med. 2008;216:109-116doi: 10.1620/tjem.216.109.
  47. Kececi H. Behcet’s disease without neurological manifestations. Tohoku J Exp Med. 2005;207:1.  doi: 10.1620/tjem.207.1.
  48. Ozisik HI, Karlidag R, Hazneci E, Kizkin S, Ozcan C. Cognitive event-related potential and neuropsychological findings in Behcet’s disease without neurological manifestations. Tohoku J Exp Med. 2005;206:15-22.  doi: 10.1620/tjem.206.15.
  49. Hirohata S. Histopathology of central nervous system lesions in Behcet’s disease. J Neurol Sci. 2008;267:41-47.  doi: 10.1016/j.jns.2007.09.041.
  50. Lisicyna TA, Vel'tishhev DJu. Psihicheskie rasstrojstva u bol'nyh revmaticheskimi zabolevanijami: diagnostika i lechenie. Nauchno-prakticheskaja revmatologija. 2015;53(5):512-521. (In Russ.).
  51. Zigmond A, Snaith RP The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.  doi: 10.1111/j.1600-0447.1983.tb09716.x.
  52. Montgomery A, Asberg MA. New depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.  doi: 10.1192/bjp.134.4.382.
  53. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:1:50-55.  doi: 10.1111/j.2044-8341.1959.tb00467.x.
  54. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561-571.  doi: 10.1001/archpsyc.1961.01710120031004.
  55. Spielberger CD. State-Trait Anxiety Inventory: Bibliography 1989 (2nd ed.). Palo Alto, CA: Consulting Psychologists Press.
  56. Lezak M, Howieson DB, Loring DW. Neuropsychological Assessment, 4th edn. Oxford University Press. New York. 2004.
  57. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-127.  doi: 10.1002/ana.1032.
  58. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69:2074-2082. doi: 10.1136/ard.2010.130476.
  59. Akman-Demir G, Saip S, Siva A. Behcet’s Disease. Curr Treat Options Neurol. 2011;13:290-310.  doi: 10.1007/s11940-011-0120-2.
  60. Shugaiv E, Tüzün E, Mutlu M, Kiyat-Atamer A, Kurtuncu M, Akman-Demir G. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behcet’s disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol. 2011;29(4 suppl 67):64-67.
  61. Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro-Behcet’s disease. A follow-up study for 4 years. Adv Exp Med Biol. 2003;528:575-578  doi: 10.1007/0-306-48382-3_117.
  62. O’Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet’s disease. Am J Med. 1984;76:75-84.  doi: ]10.1016/0002-9343(84)90753-8.
  63. Ait Ben Haddou EH, Imounan F, Regragui W et al. Neurological manifestations of Behcet’s disease: evaluation of 40 patients treated by cyclophosphamide. Rev Neurol (Paris). 2012;168:344-349.  doi: 10.1016/j.neurol.2011.09.006.
  64. Al-Araji A, Siva A, Saip S et al. Treatment of Neuro-Behcet’s disease with infliximab. An international multi-centre case-series of 18 patients. Clin Exp Rheumatol. 2010;28(suppl 60):119.
  65. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41:61-70.  doi: 10.1016/j.semarthrit.2010.09.002.
  66. Fasano A, D’Agostino M, Caldarola G, Feliciani C, De Simone C. Infliximab monotherapy in neuro-Behcet’s disease: four year follow-up in a long-standing case resistant to conventional therapies. J Neuroimmunol. 2011;239:105-107.  doi: 10.1016/j.jneuroim.2011.08.014.
  67. Giardina A, Ferrante A, Ciccia F, Vadala` M, Giardina E, Triolo G. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcet’s disease refractory to standard immunosuppressive drugs. Rheumatol Int. 2011;31:33-37.  doi: 10.1007/s00296-009-1213-z.
  68. Leccese P, D’Angelo S, Angela P, Coniglio G, Olivieri I. Switching to adalimumab is effective in a case of neuro-Behcet’s disease refractory to infliximab. Clin Exp Rheumatol. 2010;28(4):suppl 60:102.
  69. Olivieri I, Leccese P, D’Angelo S et al. Efficacy of adalimumab in patients with Behcet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29(4 suppl 67):54-57.
  70. Alty JE, Monaghan TM, Bamford JM. A patient with neuro-Behcet’s disease is successfully treated with etanercept: further evidence for the value of TNF alpha blockade. Clin Neurol Neurosurg. 2007;109:279-281.  doi: 10.1016/j.clineuro.2006.11.002.
  71. Shapiro LS, Farrell J, Borhani-Haghighi A. Tocilizumab treatment for neuro-Behcet’s disease, the first report. Clin Neurol Neurosurg. 2012;114:297-298.  doi: 10.1016/j.clineuro.2011.10.024.
  72. Nichols JC, Ince A, Akduman L, Mann ES Interferon α2а treatment of neuro-Behcet disease. J Neuroophthalmol. 2001;21:109—111.  doi: 10.1097/00041327-200106000-00011.
  73. Kato Y, Numaga J, Kato S et al. Central nervous system in a population of Behcet’s disease patients with refractory uveitis treated with cyclosporine A. Clin Exp Ophthalmol. 2001;29:335-336.  doi: 10.1046/j.1442-9071.2001.00445.x.
  74. Akman-Demir G, Ayranci O, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I. Ciclosporin for Behcet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol. 2008;26:84-90.
  75. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007;6:162-170.  doi: 10.1016/s1474-4422(07)70029-7.
  76. Seyahi E, Yurdakul S. Behcet’s syndrome and thrombosis. Mediterr J Hematol Infect Dis. 2011;3(1):2011026. doi: 10.4084/ MJHID.2011.026.
  77. Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behcet’s disease: an update. Curr Opin Rheumatol. 2011;23:24-31.  doi: 10.1097/BOR.0b013e3283410088.
  78. Aguiar de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behcet’s disease: a systematic review. J Neurol. 2011;258:719-727.  doi: 10.1007/s00415-010-5885-9.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.